Cytek Biosciences, Inc.
CTKB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $52,293 | $45,602 | $41,457 | $57,476 |
| % Growth | 14.7% | 10% | -27.9% | – |
| Cost of Goods Sold | $24,742 | $21,735 | $21,300 | $23,824 |
| Gross Profit | $27,551 | $23,867 | $20,157 | $33,652 |
| % Margin | 52.7% | 52.3% | 48.6% | 58.5% |
| R&D Expenses | $8,956 | $8,826 | $9,725 | $9,723 |
| G&A Expenses | $16,121 | $13,531 | $12,898 | $9,069 |
| SG&A Expenses | $27,787 | $25,665 | $25,407 | $20,943 |
| Sales & Mktg Exp. | $11,666 | $12,134 | $12,509 | $11,874 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $36,743 | $34,491 | $35,132 | $30,666 |
| Operating Income | -$9,192 | -$10,624 | -$14,975 | $2,986 |
| % Margin | -17.6% | -23.3% | -36.1% | 5.2% |
| Other Income/Exp. Net | $1,423 | $3,849 | $3,709 | $7,337 |
| Pre-Tax Income | -$7,769 | -$6,775 | -$11,266 | $10,323 |
| Tax Expense | -$2,291 | -$1,192 | $136 | $680 |
| Net Income | -$5,478 | -$5,583 | -$11,402 | $9,643 |
| % Margin | -10.5% | -12.2% | -27.5% | 16.8% |
| EPS | -0.04 | -0.044 | -0.09 | 0.074 |
| % Growth | 9.1% | 51.1% | -222.3% | – |
| EPS Diluted | -0.04 | -0.044 | -0.09 | 0.073 |
| Weighted Avg Shares Out | 127,548 | 126,934 | 128,339 | 129,206 |
| Weighted Avg Shares Out Dil | 127,548 | 126,934 | 128,339 | 129,206 |
| Supplemental Information | – | – | – | – |
| Interest Income | $573 | $555 | $508 | $6,152 |
| Interest Expense | $494 | $414 | $291 | $0 |
| Depreciation & Amortization | $3,060 | $2,988 | $2,884 | $2,741 |
| EBITDA | -$4,215 | -$3,373 | -$8,091 | -$2,453 |
| % Margin | -8.1% | -7.4% | -19.5% | -4.3% |